本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
PISCATAWAY, N.J., Jan. 6, 2026 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, is proud to announce its 5th Annual Biotech Global Forum, scheduled for January 14, 2026, at the San Francisco Marriott Marquis, with both in-person and virtual attendance options available. Now in its fifth year, GenScript Biotech Global Forum has become a convening platform to push the boundaries of what's possible for the global biotech ecosystem. Held alongside the annual J.P. Morgan Healthcare Conference week, the Forum brings together the scientists, innovators, investors and decision-makers to discuss the future of biotechnology – where discovery, computation and therapeutic development converge to turn scientific possibilities into patient impact. Under the theme 'Scripting Possibilities', this year's Forum will explore how transformative advancements, computational revolutions and emerging technologies redefine what is possible in cell and gene therapies (CGTs) and next-generation biotherapeutics. Attendees will engage in forward-looking discussions on the technologies and collaborations shaping next-generation biotherapeutics and accelerating the path from idea to impact. "The Global Forum has become a central gathering point for leaders driving progress across the biotech ecosystem," said Sherry Shao, CEO, GenScript Biotech Corp. "We are proud to bring this community together in San Francisco once again. Our mission is to empower researchers and companies end-to-end – with integrated technologies, platforms and expertise – from discovery to development and manufacturing through our Life Science Group and ProBio businesses. GenScript is confidently expanding its role in the industry to turn bold scientific ideas into real therapeutic impact and to accelerate the delivery of these innovations to patients worldwide." Two Visionaries Defining the Next Chapter in BiotechThe 5th Annual Biotech Global Forum will feature two globally recognized keynote speakers whose work is redefining the boundaries of science, computation, and therapeutic innovation: David Baker, PhD, Director, Institute for Protein Design; Professor of Biochemistry, University of Washington; Investigator, Howard Hughes Medical Institute; Nobel Laureate in Chemistry (2024). Dr. Baker is the pioneer of computational protein design, creating new molecules and therapeutic modalities once thought impossible and fundamentally redefining how medicines can be engineered. Eric Horvitz, PhD, MD, Chief Scientific Officer, Microsoft. Dr. Horvitz is a trailblazer in artificial intelligence and responsible AI, driving advancements that are influencing how computation accelerates biomedical research, drug development and clinical decision-making at global scale. Together, these leaders represent the convergence of biology and intelligence – where molecules are designed with algorithms and insight is amplified through AI. Forum Highlights: Keynote & Fireside Conversation: A forward-looking discussion on computational protein design, AI and the future architecture of therapeutic innovation. Insight-Driven Panel Sessions: Exploring the next frontier in cell and gene therapy, AI-enabled drug discovery and the global forces shaping biotech's evolution. Technology Showcase: Featuring GenScript's next-generation Dark Lab and GenGenius+ automation platform, demonstrating how AI and automation are transforming laboratory workflows. Advanced Therapy Spotlight: Perspectives on translating CGT innovation into scalable, clinical-ready solutions, informed by GenScript's end-to-end capabilities, including ProBio's advanced biologics and cell and gene therapy manufacturing expertise. High-Impact Networking: Connecting scientists, biotech leaders, investors and technology partners to spark collaboration and unlock new opportunities throughout the program and evening reception. "Biotechnology is at an inflection point – where speed, precision and collaboration are no longer optional," said Ray Chen, PhD, President, GenScript Life Science Group. "The Global Forum is designed to bring together the leaders scripting what comes next, and to explore ways of pushing the boundaries of what's seemingly impossible. This year's program reflects a powerful convergence – discovery science, computational intelligence and therapeutic development coming together to script what's possible next. When these forces align, scientific discoveries move faster, scale smarter and reach patients sooner." Registration for the GenScript Biotech Global Forum is now open. For more information and to register, please visit GenScript's official website. About GenScript Biotech CorporationFounded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript supports customers across the full innovation lifecycle - from early discovery and automation-driven research to advanced biologics and manufacturing - including through its ProBio business. GenScript has a team of over 5,700 employees and has served more than 200,000 customers across over 100 countries and regions. Learn more here: https://www.genscript.com. Media ContactStefanie TuckCG Lifestuck@cglife.com
MELBOURNE, Australia, Jan. 14, 2026 /PRNewswire/ -- Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX: RHY), a transformative, predictive cancer diagnostics technology company is pleased to announce the commercial launch of its updated geneTypeTM Colorectal Cancer (CRC) Risk Assessment clinical test ("geneTypeTM CRC"), a significant advancement in personalised cancer risk prediction. The updated test incorporates additional clinical and lifestyle risk factors alongside the established 140-SNP polygenic risk score (PRS), delivering improved predictive accuracy across both genders and a wider age range. The enhanced test is designed to support earlier identification of individuals at elevated risk of colorectal cancer, enabling more targeted screening pathways and complementing Rhythm's ColoSTAT® blood-based CRC detection test. Validation data for the updated model has been recently published in the peer-reviewed journal PLOS ONE (Dite GS, et al. 2025), demonstrating improved predictive performance compared to traditional approaches. Evidence suggests that approximately 50% of colorectal cancer cases could be prevented through healthy lifestyle modifications. By incorporating lifestyle risk factors known to contribute to disease risk, the enhanced geneTypeTM CRC test aims to identify a broader cohort of at-risk individuals who may benefit from earlier intervention and monitoring. Key Clinical Applications The enhanced geneTypeTM CRC Risk Assessment test has several important use-cases for this innovative new clinical test: Improved risk stratification across both genders, with particular benefits for identifying higher-risk women. Identification of younger adults at risk of early-onset colorectal cancer, supporting earlier screening interventions. Potential to encourage greater participation in bowel cancer screening programs by providing personalised risk insights. In Australia, compliance with recommended bowel cancer screening programs remains below 50%. Individuals classified as higher risk using the geneTypeTM CRC test may be candidates for closer clinical monitoring through colonoscopy, FIT testing, or Rhythm's blood-based CRC detection test, ColoSTAT®. "The enhanced geneTypeTM CRC test strengthens our ability to identify individuals at elevated risk earlier, supporting more targeted screening and complementing ColoSTAT's® role in colorectal cancer detection." said Dr Erika Spaeth, Director of Clinical Affairs at Rhythm. About Rhythm Biosciences Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.
Celltrion outlines a blueprint for innovative drug development built on its antibody expertise The company highlights its business strategy to scale U.S. manufacturing and R&D capabilities, strengthening its global supply chain, production and operations INCHEON, South Korea, Jan. 14, 2026 /PRNewswire/ -- Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today presented key strategic priorities and clinical development updates for its innovative drug pipelines including antibody-drug conjugates (ADCs) and multi-specific antibodies (msAbs) at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California. The company also highlighted plans to expand its manufacturing and R&D capabilities to support long-term growth, enhance supply resilience and reinforce its long-term commitment to the U.S. market. The presentation, composed of two sections— 'From Biosimilar Excellence to Next-Gen Innovative Therapeutics' and 'Scaling Our U.S. Presence with a Next-Gen Manufacturing and R&D Hub'—was delivered on the conference's Main Track. Celltrion's Chief Executive Officer Jin-Seok Seo and Senior Executive Vice President Hyuk-Jae Lee outlined the company's innovative drug pipeline, with plans to submit up to 16 investigational new drug (IND) applications by 2028, including up to 10 ADCs, 4 msAbs, 1 recombinant protein, and 1 peptide. In its biosimilar business, Celltrion aims to commercialize up to 18 products by 2030 and 41 products by 2038. The company's ADC candidates are designed to target solid tumor cancers; with IND applications for CT-P70, CT-P71 and CT-P73 accepted by the U.S. Food and Drug Administration (FDA) in 2025. CT-P70, a novel ADC candidate being developed for the treatment of non-small cell lung cancer (NSCLC), recently received Fast Track designation from the U.S. FDA, enabling expedited interactions throughout the development process and the potential for accelerated regulatory review. Celltrion is advancing a portfolio of msAbs that are designed to selectively target cancer cells or are activated only under specific conditions. Celltrion received an IND approval from the U.S. FDA for CT-P72, a tetravalent bispecific antibody being developed to target human epithelial growth factor receptor 2 (HER2) and cluster of differentiation 3 (CD3). "We have made significant progress and see compelling opportunities ahead. Building on our company's global footprint in biosimilar excellence, Celltrion is accelerating its transition toward next-generation innovative therapeutics," said Jin-Seok Seo, Chief Executive Officer at Celltrion. "Our expanding pipeline of ADCs and msAbs, grounded in deep antibody expertise, underscores our commitment to delivering meaningful value to patients worldwide. We aim to redefine the standard of care in oncology and beyond, while creating long-term sustainable value through scientific excellence and bold innovation." To reinforce the company's U.S. manufacturing capabilities, Celltrion recently completed the strategic acquisition of a former Eli Lilly manufacturing facility located in Branchburg, New Jersey, securing 66,000L of drug substance (DS) capacity. The company plans to sequentially increase capacity to a total of 132,000L by 2030, while also extending its capabilities to include drug product (DP) facilities. Through this acquisition, Celltrion plans to ensure long-term supply chain resilience eliminating the tariff and trade risks, ultimately strengthening its competitiveness in the U.S. market. "The acquisition of the U.S. manufacturing facility represents a pivotal step in strengthening our global supply chain and solidifying our presence in the U.S. market," said Hyuk-Jae Lee, Senior Executive Vice President at Celltrion. "By securing large-scale DS capacity in the U.S., we are enhancing supply stability, mitigating trade and tariff risks, and establishing a solid foundation for expanded R&D collaboration and innovation in the region." About Celltrion, Inc. Celltrion, Inc. is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion, Inc. is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Built on trust through our fully integrated capabilities – from advanced R&D and in-house manufacturing to a reliable global supply network – we continue moving toward innovation as we work to ensure consistent availability of affordable, trusted, and high-quality biosimilars and biologics for patients and healthcare systems across the globe. For more information, please visit our website www.celltrion.com/en-us. and stay updated with our latest news and events on our social media - LinkedIn, Instagram, X, and Facebook. FORWARD-LOOKING STATEMENT Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion, Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", "anticipates", the negative of these words or such other variations thereon or comparable terminology. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion, Inc. and its subsidiaries' management, of which many are beyond its control. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Celltrion, Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. US--26-00001 For further information please contact: Global PR Teamglobalpr@celltrion.com
SEOUL, South Korea, Jan. 14, 2026 /PRNewswire/ -- Rakuten Medical, Inc. and LOTTE Biologics today announced that they have signed a biopharmaceutical contract manufacturing agreement during the J.P. Morgan Healthcare Conference in San Francisco to strengthen Rakuten Medical's production capabilities for its innovative oncology therapy, Alluminox® platform-based photoimmunotherapy. Signing ceremony held during the J.P. Morgan Healthcare Conference Under the agreement, LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates, supporting Rakuten Medical's global clinical development and future commercialization. Rakuten Medical's proprietary photoimmunotherapy technology is designed to selectively target cells in solid tumors, by combining cell-targeting moieties, such as antibodies, with light-activatable agents, enabling focal and selective destruction of solid tumor cells upon light exposure. In Japan, the therapy is approved for recurrent head and neck cancer, and its footprint has expanded steadily, through broader site adoption and sustained year–over–year growth in treatment numbers. In parallel, a global Phase 3 clinical trial is underway in the United States, Taiwan region and Japan, with plans to start treatment in Ukraine and Poland soon. Rakuten Medical also plans to initiate a Phase 1 clinical trial in Japan for other solid tumors beyond head and neck cancer this year. These clinical and commercial dynamics are driving increased demand for Rakuten Medical's bioconjugates. LOTTE Biologics has been expanding its capabilities as a global contract development and manufacturing organization (CDMO), particularly in the field of monoclonal and multispecific antibodies, antibody-drug conjugates (ADCs), and advanced bioconjugation services. LOTTE Biologics will support the production of monoclonal antibody intermediates and their conjugates for Rakuten Medical's programs, through its specialized ADC manufacturing facility at the Syracuse Bio Campus in New York. The facility is equipped with dedicated ADC production capabilities and advanced bioconjugation technologies, enabling the company to deliver high-quality manufacturing services while meeting global regulatory requirements and ensuring stable supply for customers worldwide. About LOTTE Biologics Founded in 2022 and headquartered in Seoul, South Korea, LOTTE Biologics operates integrated biologics facilities in the United States and South Korea. Through a unified Dual Hub Service model, LOTTE Biologics enhances supply security, supports manufacturing scalability, and maintains consistent quality standards across regions. LOTTE Biologics provides modular, phase-appropriate manufacturing solutions spanning preclinical through commercial stages, with proven capability in producing mammalian-cell-based biologics, including monoclonal antibodies, fusion proteins, and multispecific modalities. At the Syracuse Bio Campus in New York, LOTTE Biologics delivers high-quality GMP drug substance manufacturing supported by more than 62 global regulatory approvals. The site offers 40,000 L of total capacity across eight 5,000 L stainless steel bioreactors and includes analytical and warehouse infrastructure. In addition, the company has expanded into Antibody-Drug Conjugates (ADCs) through strategic investment in onsite conjugation suites, enabling a streamlined, end-to-end pathway from biologic drug substance production to ADC manufacturing within a single campus. In South Korea, LOTTE Biologics is constructing three advanced bio plants at the Songdo Bio Campus. With the first facility already underway and scheduled for operation in 2027, each plant will include eight 15,000 L stainless steel bioreactors for commercial production, supported by multiple 3,000 L bioreactors for clinical-scale needs. Collectively, these plants will provide a manufacturing volume exceeding 360,000L in bioreactor capacity. Guided by the vision "Possibilities Beyond Limits," LOTTE Biologics is committed to serving as a long-term, trusted partner, supporting efficient scale-up, dependable manufacturing execution, and the continuous advancement of clients' therapeutic programs. More information about LOTTE Biologics, please visit: www.lottebiologics.com About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing its Alluminox® platform-based photoimmunotherapy, which has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in five countries/regions, including the United States, where it is headquartered, Japan, Taiwan region, Switzerland and India. For more information, visit www.rakuten-med.com. About the Alluminox® Platform The Alluminox® platform is Rakuten Medical's investigational technology that combines pharmaceuticals, medical devices, medical technology and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration, and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690 nm) to transiently activate the drug. Rakuten Medical's preclinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical's Alluminox platform-based photoimmunotherapy is investigational.
NANTONG, China, Jan. 13, 2026 /PRNewswire/ -- Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral sclerosis (ALS). The initial dosing occurred at Second Affiliated Hospital, Zhejiang University School of Medicine, under the leadership of Dr. Zhi-Ying Wu, head of the Department of Medical Genetics/Center for Rare Diseases. This Phase II trial is a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of repeated intrathecal injections of RAG-17 in patients with SOD1 mutations. The participating sites include Beijing Tiantan Hospital, Capital Medical University (led by Dr. Yi-Long Wang), The Second Affiliated Hospital, Zhejiang University School of Medicine (led by Dr. Zhi-Ying Wu), West China Hospital of Sichuan University (led by Dr. Hui-Fang Shang), Fujian Medical University Union Hospital (led by Dr. Zhan-Yu Zou) and the First Affiliated Hospital, Sun Yat-sen University (led by Dr. Jing-Sheng Zeng) . This milestone marks the progression into the Phase II stage of the study, building on the successful completion of the Phase I single ascending dose (SAD) portion. The transition to the Phase II MAD phase was supported by highly encouraging data from the SAD study, which demonstrated an exceptional safety profile and sustained biomarker modulation following a single injection, including significant reductions in CSF SOD1 protein and improvements in plasma neurofilament light chain (NfL) levels. These results validate the capability of our proprietary SCAD™ delivery platform for central nervous system (CNS) in humans. Dr. Long-Cheng Li, Founder and CEO of Ractigen Therapeutics, emphasized Ractigen's dedication to advancing treatments for ALS: "The successful dosing of the first patient represents a significant milestone in our mission to develop transformative therapies for ALS. The positive results from the Phase I trial affirm the promise of RAG-17 and provide us with strong confidence in its potential to markedly improve the lives of patients suffering from SOD1-mutated ALS." Dr. Zhi-Ying Wu shared optimistic expectations for the Phase II trial: "We are excited to be part of this important study. Based on the improvements we have observed clinically, we look forward to further investigating RAG-17's potential to enhance the quality of life for ALS patients as we progress." About RAG-17RAG-17 is an investigational siRNA therapeutic candidate designed using Ractigen's proprietary SCAD™ delivery platform technology to specifically target and silence the superoxide dismutase 1 (SOD1) gene mRNA. Mutations in the SOD1 gene cause a toxic gain-of-function and are a known cause of familial ALS. By reducing the production of the toxic mutant SOD1 protein, RAG-17 aims to slow or halt the progression of SOD1-ALS. RAG-17 has obtained Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) and been selected for the CARE Program of the Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA), which facilitates the accelerated development of rare disease therapies. About ALSAmyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease affecting nerve cells in the brain and spinal cord, leading to muscle weakness, paralysis, and ultimately death, typically within three to five years of diagnosis. SOD1 gene mutations account for approximately 10-20% of familial ALS cases and about 1-2% of sporadic ALS cases. There remains a critical unmet medical need for effective treatments that can slow or stop disease progression. About Ractigen TherapeuticsRactigen Therapeutics is a clinical-stage biopharmaceutical company innovating next-generation RNA therapeutics, with a primary focus on small activating RNAs (saRNAs) developed through its clinically validated RNA activation (RNAa) technology. Leveraging proprietary delivery platforms such as SCAD™, LiCO™, and GLORY™, Ractigen is advancing a robust pipeline addressing unmet medical needs in oncology, neurological diseases, and genetic disorders. Its versatile technologies also enable the rapid development of RNA-based solutions, including siRNAs, where applicable, to target life-threatening, fast-progressing conditions such as those in the CNS. Committed to scientific excellence and patient-centered innovation, Ractigen strives to transform healthcare through the power of RNA therapeutics. For more information, visit www.ractigen.com.
Embodying a New Model of Inter-generational Enterprise Anchored in Healthcare, Finance and Education SINGAPORE, Jan. 13, 2026 /PRNewswire/ -- As Leo International Group approaches its centennial year in 2026, the Group is not merely commemorating a hundred years of legacy and commercial success. With the formal relocation of its global headquarters to Singapore and the planned inauguration of its Family Office, Leo International Group is using this historic milestone to articulate its next century design; a renewed vision for what a modern enterprise must stand for in a rapidly changing world – one defined not by scale or momentum alone but by longevity, responsibility and contribution across generations. Leo International Group Chairman and Chairman of Leo International Precision Health AG, Mr Leo Wang, at the Frankfurt Stock Exchange (Photo Credit: martinjoppen.de) Ringing of the Bell for Leo International Precision Health AG at the Frankfurt Stock Exchange in November 2025 (Photo credit: martinjoppen.de) While the Wang family enterprise traces its origins to 1926, Leo International Group itself was formally established in 2022 under the leadership of Mr Leo Wang, Chairman and Founder. A fourth-generation steward, Mr Wang is leading a comprehensive institutional re-design that translates a century-old heritage of service, philanthropy and multi-sector enterprise into a globally governed, purpose-driven and future-ready group. Rather than treating the centennial as a retrospective celebration, the Group is positioning its centennial year as a strategic inflection point, marking its transition into an inter-generational conglomerate designed to operate across continents, industries and generations. "We are using this moment to confront pressing questions: What must a modern enterprise stand for if it intends to remain relevant for the next hundred years? In what ways can a company remain meaningful to society and be trusted across generations? A century ago, enterprises were built to survive and expand. Longevity today is determined not by scale alone but by whether an enterprise continues to serve society, earns trust across generations, and possesses governance discipline. Our mission is to design for the next hundred years," said Mr Leo Wang, Chairman of Leo International Group. Singapore was chosen as the Group's global headquarters not merely for its well-established connectivity and robust financial infrastructure but for its role as a jurisdiction synonymous with rule of law, regulatory maturity and long-term capital stewardship. "The establishment of our Family Office alongside the relocation of our HQ to Singapore reflects the Group's intention to anchor its next century of growth within a governance-first framework, where capital, strategy and responsibility are aligned over the long term. Singapore is precisely the environment required to design governance that can endure beyond any single generation or individual leader," Mr Wang added. From Industrial Foundations to Institutional Design Leo International Group traces its origins to early industrial and trading activities established by Mr Wang's family in 1926, laying foundations that evolved through logistics, infrastructure, trade and community development over successive decades. While his family's business expanded steadily across multiple business lines in the latter half of the twentieth century, its most profound transformation began when Mr Wang returned, following nearly two decades of senior leadership roles in century-old multinational corporations across Europe and the United States including Goodyear, Swarovski, and the Swire Group. Mr Wang departed The Goodyear Tire & Rubber Company in 2020 and then laid the foundation for Leo International Group in 2021. After a year of strategic planning, structural formation and governance set-up, the Group formally commenced operations in 2022. "Drawing on decades of exposure to century-old European and American corporations that had survived wars, industrial shifts, technological disruption and changing consumer values, my experience taught me this: the DNA of a century-old enterprise must be etched with discipline and altruism because if those remain intact, the organisation can navigate change without losing its direction. Truly long-lived enterprises are not built on a single visionary strategy or charismatic founder. They are built on accumulated institutional capability: governance discipline, cultural coherence, and sustained contribution to society," said Mr Wang. "Across industries and geographies, I observed a consistent pattern – enduring enterprises do not treat success as an endpoint. They treat it as something that must be institutionalised, replicable, inheritable, and capable of self-correction. A centennial blueprint, therefore, is not a vision deck. It is an exercise in institutional design. If a company requires one individual's brilliance to operate, it will not survive generational transition," he added. This philosophy now underpins Leo International Group's redefined structure: a group architecture anchored in three inter-generational core pillars, namely healthcare, financial services and education, supported by an integrated premium lifestyle and services ecosystem designed to serve ultra-high-net-worth (UHNW) families over the long term. Three Pillars for the Next Century At the heart of Leo International Group's centennial strategy lies a calibrated prioritisation of sectors that Mr Wang describes as "inter-generational by nature." Healthcare, finance and education were not selected as a diversified portfolio but as a mission-driven hierarchy – industries that address humanity's most fundamental and enduring needs. "When you think in quarters, many industries appear attractive. When you think in centuries, only a few sectors truly endure. Healthcare, finance and education are inter-generational industries because they address the three most fundamental human constants: life, order and future. These three sectors share one defining characteristic: they transcend generations and directly impact human dignity and choice. Healthcare protects life itself. Finance governs how value is preserved and transferred. Education shapes how far societies and enterprises can go in the future," said Mr Wang. "A century-old enterprise is held together by systems that can self-correct and self-renew, and constantly adapt to evolving conditions in the environment. That is why we anchor the next century on three pillars – healthcare, finance, and education – industries that demand trust, long-term governance, and that carry civilisational impact. Around these pillars, we build a comprehensive and elegant lifestyle and premium services ecosystem designed to serve UHNW clients holistically over time," he elaborated. Beyond its three core pillars, Leo International Group operates across a range of lifestyle and service domains including yachts and marinas, hospitality, private aviation, art and fashion, super cars and equestrian offerings. "Ultra-high-net-worth families are not buying products; they are buying continuity and peace of mind. Lifestyle platforms create trust, proximity and long-term relationships. Without that trust, even the best healthcare, financial or educational systems cannot truly serve a family," Mr Wang explained. That is why the comprehensive suite of luxury and premium lifestyle services functions as the connective tissue that naturally integrates health, capital, and next-generation development – medical arrangements for mobility, education embedded within family journeys, financial trust-building within elite networks, and the lifestyle nodes required for cross-border governance. "Our differentiation is simple: many competitors sell luxury products or experiences; we build synergistic long-term relationships. We do not optimise for one-time extravagance. We optimise for repeatable reliance through quality service systems and governance credibility. That is ultimately why UHNW families entrust you with their legacy planning and continuity," Mr Wang added. Healthcare Healthcare has emerged as the most rigorously governed and publicly accountable pillar associated with Mr Wang's broader centennial vision. Within his personal business and investment portfolio, Leo International Precision Health AG (LIPH) serves as the flagship healthcare platform, operating independently while reflecting the same governance philosophy that underpins Leo International Group's long-term strategy. LIPH has recently successfully completed a listing on the Frankfurt Stock Exchange Main Board, placing the platform within one of the world's most stringent life-sciences regulatory environments. The Frankfurt listing reflects a deliberate alignment with European governance standards that prioritise clinical evidence, transparency, long-term safety and accountability. Following its listing, LIPH announced the completion of the acquisition and integration of six majority-owned portfolio companies on 17 December 2025. These entities span AI diagnostics, biomedical research, immunology, biotechnology and clinical care delivery across Asia-Pacific and the United States. Together, they form an AI-driven precision health platform designed to connect discovery, diagnosis, therapeutics and real-world clinical delivery within a coherent system. Europe is a market to be targeted in the next phase. "With ageing demographics around the world, chronic disease burdens, and AI-driven clinical transformation, healthcare becomes increasingly central. The Frankfurt mainboard represents one of the world's most rigorous regulatory cultures for healthcare and life sciences. It requires accountability not only to shareholders, but also to patients, society and future generations," said Mr Wang, who is also Chairman of Leo International Precision Health AG. Finance With Singapore as its new global headquarters, Leo International Group is in the process of establishing a Family Office to serve as an international governance and capital management hub, aligning family capital with long-term healthcare, education and stewardship objectives. "Finance, as we define it, is not about short-term wins. It is about inter-generational governance – creating durable order across regulation, asset allocation, and risk management so that family capital becomes fuel for education, innovation, philanthropy, and long-term enterprise," said Mr Wang. Preparations to set up the Family Office are now underway, with the Group currently finalising the appointment of external advisers. The end-to-end process is expected to take approximately 12 to 18 months. "We intend to build a cross-market, cross-asset, inter-generational governance framework which is anchored by a family office as an international hub, leveraging mature regulatory standards, transparency, and capital management to connect wealth continuity with education and health needs across geographies and generations," he added. The Group's financial services strategy is therefore structured around long-term asset stewardship, regulatory discipline and inter-generational continuity, rather than short-term optimisation. Singapore's highly regarded regulatory environment, transparency standards and strong capital governance frameworks provide a conducive foundation for this approach. Education Education represents the longest investment horizon within the Group's portfolio. The Wang family has already established kindergartens and experimental primary schools, which are in the process of being consolidated into Leo International Group. In parallel, the Group is actively acquiring secondary schools and a university, while also identifying suitable land parcels in Kuala Lumpur and Tokyo for the development of international schools – laying the foundation for a scalable and cross-border education platform. Over time, these education assets are intended to be institutionally structured and prepared for a future listing on the Singapore Exchange. "Education goes even further. It shapes values, the quality of decisions, leadership, and the foundational capacity of civilisation itself. If an enterprise intends to endure for a century, its ultimate competitive advantage is not capital. It is people – whether the next generation possesses worldview, ethical discipline, and leadership maturity," Mr Wang added. Capital Markets as Governance Architecture A defining feature of Leo International Group's next-century design is its distributed capital markets strategy, aligning different business pillars with the most optimal global exchanges. Healthcare has already been anchored in Frankfurt under the Chairman's personal business and investment portfolio. Education, finance, technology, hospitality and real estate assets are planned for future listings across Singapore, Taipei, Hong Kong, the NYSE and NASDAQ. "This is not about diversification for its own sake. It is about governance alignment. Each industry must grow under the regulatory culture and investor discipline best suited to its nature. Our multi-exchange architecture is a 'sector-fit + governance-fit' design," Mr Wang explained. Leo International Group in the next centennial From its beginnings in Taiwan in 1926, Leo International Group now operates across 10 vital domains, collaborating with more than 100 strategic partners and encompassing over 1,000 world-renowned brands. It is defined as the most comprehensive and inter-generational solutions platform for UHNW clients – one that integrates 10 value sectors across healthcare, finance, education, and premium lifestyle services into a long-term and trust-based relationship that is cross-border by design. "Most importantly, I want Leo International Group to be synonymous with a purpose- and mission-led enterprise. When we talk about altruism, it is not a slogan – it is a governance logic: capital should help heal and uplift, not merely expand itself. That is the 'time significance' that we would like the centennial to represent," said Mr Wang. About Leo International Group Ten Key Sectors of Leo International Group Leo International Group is a multi-sector global enterprise delivering a comprehensive ecosystem of luxury lifestyle services for discerning and ultra-high-net-worth individuals, families, and institutions. While the Wang family enterprise traces its origins to 1926, Leo International Group was formally established in 2022 under the leadership of its Chairman and Founder, Mr Leo Wang. Approaching its centennial heritage milestone in 2026, Leo International Group operates a cohesive ecosystem designed to support long-term health, wealth preservation, education, and lifestyle excellence across generations. The Group operates across ten key sectors – Asset Management, Technology, Yacht, Equestrian, Art & Fashion, Medical Care, Education, Super Car, Private Jet, and Leisure. Each sector is governed to the highest institutional standards and strategically integrated to provide premium service excellence, and seamless and sustainable long-term value. Headquartered in Singapore with an international footprint, Leo International Group is guided by global perspectives, disciplined governance, capital-market rigor, and cultural stewardship. For more information, please visit www.leointernationaltaiwan.com.
A12 藝術空間
Biotechnology
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
